Bambusa Therapeutics Welcomes Todd James as New Chief Financial Officer

Bambusa Therapeutics, Inc., a clinical-stage biotechnology firm, has announced the notable appointment of Todd James as its Chief Financial Officer (CFO). This transition, officially revealed on March 19, 2026, comes at a crucial juncture for the company as it endeavors to enhance its clinical pipeline of next-generation bispecific antibodies designed to tackle immunological and inflammatory conditions (II).

Strengthening Financial Leadership

Mr. James brings over two decades of extensive experience in the biopharmaceutical sector, having honed his skills particularly in capital markets, investor relations, and corporate strategy. Prior to this role, he played integral positions at Acceleron Pharma until its substantial acquisition by Merck, as well as at Viridian Therapeutics. His in-depth understanding of the financial landscape is poised to lead Bambusa's financial strategy while fostering key stakeholder relationships.

Dr. Shanshan Xu, the founder and CEO of Bambusa Therapeutics, expressed enthusiasm about Mr. James's appointment, emphasizing his well-established track record in capital market executions and strategic guidance. Dr. Xu noted, "His proven ability to support long-term value creation will be pivotal as we continue to innovate and expand our clinical programs."

The Task Ahead

As Bambusa's new CFO, Mr. James's responsibilities include steering the company’s financial strategies while sustaining engagement with external stakeholders. Bambusa is currently advancing its innovative bispecific antibody pipeline towards what the company refers to as its 2+2 vision, which focuses on developing BBT001 and BBT002 for pivotal studies, as well as propelling BBT003 and BBT004 into proof-of-concept studies slated for 2028. Each of these initiatives represents a significant leap forward in the treatment of various immune-mediated diseases.

Career Background

Over his distinguished career, Mr. James has amassed profound experience within the biopharmaceutical domain, where he has excelled in roles that required sharp financial insights. His previous tenure at Acceleron from 2015 to 2021 saw him spearheading the company's investor relations and corporate communications, where his leadership significantly contributed to raising over $1 billion for strategic financing initiatives. His recognized excellence in investor relations has earned him the title of the Best Investor Relations Professional in Biotechnology by Institutional Investor magazine.

Moreover, before his influential roles at Acceleron and Viridian, Mr. James dedicated nine years at Trout Group and Trout Capital, serving as an advisor to biopharmaceutical companies on matters related to investor relations and capital acquisition. He began his career within the Biotechnology Capital Markets Intelligence team at Thomson Financial.

Looking Forward

Reflecting on his new role, Mr. James stated, "I am thrilled at the opportunity to join Bambusa, a biopharmaceutical innovator focused on II therapies. I am excited to collaborate with the talented team to enhance Bambusa's financial approach while committing to our mission of delivering groundbreaking medications across various illness domains."

About Bambusa Therapeutics

Bambusa Therapeutics is leading in the development of distinct therapeutic solutions for chronic diseases through its innovative antibody engineering platform. With a focus on creating the next generation of II therapeutics, Bambusa strives to provide transformative medical options that significantly improve patient outcomes at every life stage. Their lead candidates, such as BBT001 and BBT002, are poised to make a notable impact in treating conditions related to atopic dermatitis and type 2 inflammatory disorders. As they champion their clinical goals, the company's vision underscores a commitment to patient-centric healthcare enhancements.

In summary, Todd James's arrival at Bambusa Therapeutics heralds a new chapter in financial management and strategic growth, reinforcing the company's ambition to lead in the biopharmaceutical landscape dramatically.